Siefker-Radtke, A. O. Emerging therapies in the treatment of bladder cancer. J. Natl Compr. Cancer Netw. 21 (5.5), 1–3 (2023).

Google Scholar 

Cathomas, R. et al. The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma. Eur. Urol. 81, 95–103 (2021).

Article  PubMed  Google Scholar 

Vilaseca, A. et al. Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non-muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) harboring select FGFR mutations or fusions: phase 1 first-in-human study. J. Clin. Oncol. 41, TPS583 (2023).

Article  Google Scholar 

Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218–1230 (2020).

Article  PubMed  CAS  Google Scholar 

Rosenberg, J. E. et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann. Oncol. 34, 1047–1054 (2023).

Article  PubMed  CAS  Google Scholar 

Van Der Heijden, M. S. et al. Nivolumab plus gemcitabine–cisplatin in advanced urothelial carcinoma. N. Engl. J. Med. 389, 1778–1789 (2023).

Article  PubMed  Google Scholar 

Powles, T. et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N. Engl. J. Med. 390, 875–888 (2024).

Article  PubMed  CAS  Google Scholar 

Meric-Bernstam, F. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J. Clin. Oncol. 42, 47–58 (2024).

Article  PubMed  CAS  Google Scholar 

Wahida, A. et al. The coming decade in precision oncology: six riddles. Nat. Rev. Cancer 23, 43–54 (2023).

Article  PubMed  CAS  Google Scholar 

Loriot, Y. et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 389, 1961–1971 (2023).

Article  PubMed  CAS  Google Scholar 

Clinton, T. N. et al. Genomic heterogeneity as a barrier to precision oncology in urothelial cancer. Cell Rep. 41, 111859 (2022).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Faltas, B. M. et al. Clonal evolution of chemotherapy-resistant urothelial carcinoma. Nat. Genet. 48, 1490–1499 (2016).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Gerlinger, M. et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat. Genet. 46, 225–233 (2014).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bolenz, C. et al. Increasing biomarker guidance in the treatment of urothelial carcinoma: systematic review of international clinical trials. Urol. Int. 107, 480–488 (2023).

Article  PubMed  CAS  Google Scholar 

Erlmeier, F. et al. Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. Eur. Urol. 83, 133–142 (2022).

Article  PubMed  Google Scholar 

Amir, E. et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J. Clin. Oncol. 30, 587–592 (2012).

Article  PubMed  Google Scholar 

Sharma, M., Gogia, A., Deo, S. S. V. & Mathur, S. Role of rebiopsy in metastatic breast cancer at progression. Curr. Probl. Cancer 43, 438–442 (2019).

Article  PubMed  Google Scholar 

Klümper, N. et al. Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. Clin. Cancer Res. 29, 1496–1505 (2022).

Article  PubMed Central  Google Scholar 

Hu, C. & Dignam, J. J. Biomarker-driven oncology clinical trials: key design elements, types, features, and practical considerations. JCO Precis. Oncol. 3, PO.19.00086 (2019).

PubMed  PubMed Central  Google Scholar 

LoRusso, P. M. & Freidlin, B. Improving precision oncology through better designs and reporting of biomarker-driven randomized clinical trials. J. Natl Cancer Inst. 115, 122–124 (2022).

Article  PubMed Central  Google Scholar 

Warrick, J. I. et al. Intratumoral heterogeneity of bladder cancer by molecular subtypes and histologic variants. Eur. Urol. 75, 18–22 (2019).

Article  PubMed  CAS  Google Scholar 

Choi, W. et al. Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur. Urol. 72, 354–365 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Lamy, P. et al. Paired exome analysis reveals clonal evolution and potential therapeutic targets in urothelial carcinoma. Cancer Res. 76, 5894–5906 (2016).

Article  PubMed  CAS  Google Scholar 

Thomsen, M. B. H. et al. Spatial and temporal clonal evolution during development of metastatic urothelial carcinoma. Mol. Oncol. 10, 1450–1460 (2016).

Article  PubMed  PubMed Central  Google Scholar 

Williams, M. J., Werner, B., Barnes, C. P., Graham, T. A. & Sottoriva, A. Identification of neutral tumor evolution across cancer types. Nat. Genet. 48, 238–244 (2016).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Shi, M.-J. et al. APOBEC-mediated mutagenesis as a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur. Urol. 76, 9–13 (2019).

Article  PubMed  CAS  Google Scholar 

Shi, M.-J. et al. Reply to Alexander Yang, Vincent L. Cannataro, Jeffrey P. Townsend’s Letter to the Editor, re: Ming-Jun Shi, Xiang-Yu Meng, Philippe Lamy, et al. APOBEC-mediated mutagenesis as, a likely cause of FGFR3 S249C mutation over-representation in bladder cancer. Eur. Urol. 77, e26–e27 (2020).

Article  PubMed  Google Scholar 

Meeks, J. J. et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat. Rev. Urol. 17, 259–270 (2020).

Article  PubMed  PubMed Central  Google Scholar 

Liu, D. et al. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. Nat. Commun. 8, 2193 (2017).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov. 5, 704–712 (2015).

Article  PubMed  PubMed Central  CAS  Google Scholar 

Li, Q. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle-invasive bladder cancer. Clin. Cancer Res. 25, 977–988 (2019).

Article  PubMed  CAS  Google Scholar 

Gil-Jimenez, A. et al. Assessment of predictive genomic biomarkers for response to cisplatin-based neoadjuvant chemotherapy in bladder cancer. Eur. Urol. 83, 313–317 (2023).